JAN 02, 2020 9:53 AM PST

FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer

WRITTEN BY: Annie Lennon

In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer drug developed by pharmaceutical firm AstraZeneca, to treat patients with advanced stages of the disease. 

Dave Fredrickson, executive vice president of AstraZeneca’s oncology business unit said, “Patients with advanced pancreatic cancer historically have faced poor outcomes due to the aggressive nature of the disease and limited treatment advances over the last few decades.”

Research has suggested that certain variants of the BRCA1 and BRCA2 genes increase one’s risk of developing pancreatic cancer. With normal versions of these genes producing proteins that regulate cells’ ability to both identify and repair damaged DNA, certain variants are unable to do this. These thus lead to the production of malfunctioning proteins, which in turn allow healthy cells to transform into cancer cells, and form tumors.

To combat this process, researchers developed Lynparza, a Poly ADP ribose polymerase (PARP) inhibitor. A protein that repairs a different type of DNA damage than BRCA variants, it disables cells with faulty BRCA from repairing themselves, meaning that, rather than developing into cancer cells, they simply die. 

Clinical trials investigating the drug’s efficacy were positive. Victoria Manax MD., the Chief Medical Officer of Pancreatic Cancer Action Network (PanCAN) said, “The clinical trial results showed a certain subset of metastatic pancreatic cancer patients had a good response to a PARP inhibitor called Lynparza (olaparib) if their tumor had already responded to platinum-containing chemotherapy.” 

She continued, “In the 151 patients treated through this trial, 22.1 percent of patients who received Lynparza had no disease progression two years after starting the treatment, as compared to 9.6 percent of patients who did not receive Lynparza.”

An effective treatment option for those with germline BRCA mutations, the drug should be able to treat between 4 and 7% of pancreatic cancer patients. Julie Fleshman, President and CEO of PanCAN said, “Lynparza is a great example of this big step forward in improving patient outcomes and further confirms the need for all patients to get appropriate testing to determine the best treatment option for them.”



Sources: Pancan 2017, Pancan June 2019Pancan December 2019 and 10tv

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 01, 2022
Drug Discovery & Development
The Impact of AI on Drug Discovery
The Impact of AI on Drug Discovery
Artificial Intelligence, also known as “AI”, has been the talk of the past year. AI performs and responds to ...
DEC 11, 2022
Immunology
The First Drug That Can Delay Type 1 Diabetes Onset is Approved
The First Drug That Can Delay Type 1 Diabetes Onset is Approved
About 30,000 people are diagnosed with type 1 diabetes every year in the United States, and it's a common chronic diseas ...
JAN 12, 2023
Drug Discovery & Development
Blood Pressure Drug Could Treat PTSD in Veterans
Blood Pressure Drug Could Treat PTSD in Veterans
A drug used to treat blood pressure and ADHD may be able to mitigate PTSD symptoms. The corresponding study was publishe ...
JAN 18, 2023
Drug Discovery & Development
Slowing breast tumor growth with intravenous delivery of tumor suppressor genes
Slowing breast tumor growth with intravenous delivery of tumor suppressor genes
According to the American Cancer Society, breast cancer accounts for 30% of newly diagnosed invasive cancers in women. I ...
JAN 25, 2023
Cancer
Pregnancy After, or During, Breast Cancer
Pregnancy After, or During, Breast Cancer
Breast cancer remains the most common cancer in women in the United States.  Experts estimated 287,850 breast cance ...
JAN 27, 2023
Cancer
A New Immunotherapy Approach for Advanced Colorectal Cancer
A New Immunotherapy Approach for Advanced Colorectal Cancer
With estimates of over 150,000 new cases and over 50,000 deaths in 2022, colorectal cancer (CRC) remains one of the top ...
Loading Comments...